3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Terminated
1
Sponsor Class
NIH
4
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
56
Lung Neoplasms
48
Leukemia, Myeloid, Acute
44
Breast Neoplasms
37
Carcinoma, Non-Small-Cell Lung
36
Myelodysplastic Syndromes
27
Pancreatic Neoplasms
24
Leukemia, Lymphocytic, Chronic, B-Cell
24
Multiple Myeloma
23
Colorectal Neoplasms
23
Carcinoma, Renal Cell
22
Neoplasm Metastasis
20
Melanoma
20
Glioblastoma
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Ovarian Neoplasms
17
Lymphoma, Large B-Cell, Diffuse
17
Brain Neoplasms
16
Triple Negative Breast Neoplasms
14
Squamous Cell Carcinoma of Head and Neck
12
Carcinoma, Hepatocellular
12
Lymphoma, Mantle-Cell
11
Lymphoma, B-Cell
11
Leukemia, Myelomonocytic, Chronic
11
Fallopian Tube Neoplasms
11
Rectal Neoplasms
10
Myeloproliferative Disorders
10
Lymphoma, Follicular
10
Colonic Neoplasms
10
Hematopoietic and Lymphatic System Neoplasm
9
Interventions
Radiotherapy
9
Doxorubicin
7
pazopanib
5
palbociclib
4
Trabectedin
4
Gemcitabine
4
ribociclib
3
pembrolizumab
3
eribulin
3
Magnetic Resonance Spectroscopy
3
selinexor
2
liposomal doxorubicin
2
avelumab
2
abemaciclib
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Immunoglobulin G
2
Ifosfamide
2
Docetaxel
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
sotigalimab
1
sodium thiosulfate
1
sitravatinib
1
silmitasertib
1
sargramostim
1
romidepsin
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Liposarcoma
×
Specimen Handling
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled